Highlights
Canadian Men’s Health Foundation reports that more men are addressing stress, anxie
CMHF is helping more men tackle chronic stress, anxiety and depression with the MindFit Toolkit, presented by TELUS Heal
Unlocking the small molecules: Metabolomics for precision health
The emerging field of metabolomics is shifting the conversation around human health towards a personalized approach that
Cormica Bradford expands testing capabilities with equipment
Cormica Bradford, a division of Cormica, has expanded its laboratory capabilities.
UK health campaigners renew calls for ban on energy drink sales to children
More than 40 health organisations are calling on policy makers to restrict sales of energy drinks to children.
The Turmeric Co. study finds vitamin shot may prevent post-exercise gut damage in athletes
New research in male elite footballers reveals reduced incidences of upper respiratory symptoms (URS) and gastrointestin
FDA Approves AI Device That Helps Spot Skin Cancer
THURSDAY, Jan. 18, 2024 (HealthDay news) -- The first medical device powered by artificial intelligence and designed to
Research links vitamin K2 and D to predictor of cardiovascular disease
A new data analysis suggests a link between vitamin K2 MK-7 and vitamin D supplementation and a reduction in coronary ar
Many Closeted Gay Men Didn't Receive Mpox Care During Outbreak
THURSDAY, Jan. 18, 2024 -- Too many closeted gay and bisexual men didn't receive treatment for infectious mpox durin
Non-White U.S. Kids Get Worse Pediatric Care
THURSDAY, Jan. 18, 2024 -- Pediatric care for kids who aren’t white is worse across the United States, a new study
Xenco Medical unveils TrabeculeX Continuum
Medical technology company Xenco Medical has unveiled TrabeculeX Continuum, a convergent technology bridging digital
Health Equity Has a Direct Impact On the Organization
Health equity contributes to business performance and profits. Making health equity a priority should be part of ever
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Ta
nlData demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including th